Vasopressin-2 receptor antagonist peptides and uses thereof
Summary
The USPTO has granted Patent US12595288B2 to Commissariat à l'Énergie Atomique et aux Énergies Alternatives covering vasopressin-2 receptor antagonist peptides. The patent protects peptide sequences with at least 80% amino acid identity to SEQ ID NO. 1, with specific modifications at variable positions enabling therapeutic applications. The grant includes 14 claims.
What changed
USPTO granted Patent US12595288B2 to Commissariat à l'Énergie Atomique et aux Énergies Alternatives for vasopressin-2 receptor antagonist peptides. The patent claims protect a specific peptide sequence formula with variable amino acid residues at positions X1-X6, where X1 is F or G, X2 is any non-basic amino acid, X3 is T or D, X4 is I, L, or E, and X5/X6 are either V/G or G/V combination, with alanine at position 39. The peptides have diagnostic and therapeutic uses.
For pharmaceutical and biotech companies developing vasopressin-related therapeutics, this patent establishes intellectual property barriers for similar peptide designs. The assignee now holds exclusive rights to these specific sequence configurations for diagnostic and therapeutic applications, potentially affecting research and development paths in this therapeutic area.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Vasopressin-2 receptor antagonist peptides and uses thereof
Grant US12595288B2 Kind: B2 Apr 07, 2026
Assignee
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Inventors
Nicolas Gilles, Justyna Ciolek, Laura Droctove, Bernard Maillere, Herve Nozach
Abstract
A peptide may include a sequence having 80% or more amino acid identity with the amino acid sequence of SEQ ID NO. 1, i.e., RPSX1CNLPVKPGPCX2GFFSAFYYSQKX3NKCHSFTYGGCAGNANRFSTX4EKCRRTC X5X6, wherein, X1 is the amino acid residue F or G, X2 is any amino acid residue, except a basic amino acid residue, X3 is the amino acid residue T or D, X4 is the amino acid residue I, L, or E, (i) X5 is V and X6 is G or (ii) X5 is G and X6 is V, and the amino acid located at position 39 is A. Such peptides may have various diagnostic and therapeutic uses.
CPC Classifications
C07K 14/46 A61K 38/17 C12N 15/63 G01N 33/5008 G01N 2333/72
Filing Date
2021-06-23
Application No.
18002625
Claims
14
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.